REPRIEVE is evaluating if a statin medication (pitavastatin calcium) is effective to prevent heart disease among people with HIV.
REPRIEVE is the largest randomized trial to date in HIV and results from REPRIEVE will help clinical researchers and clinical care providers to develop heart disease prevention and treatment guidelines, specifically for people with HIV.
REPRIEVE leadership celebrates reaching target accrual of 7500 participants. Congratulations to the University of Southern California site team for enrolling the 7500th participant!
Number of Participants
Percentage of Women
Mean Years Living with HIV